肝硬化患者非肝脏共病不影响认知表现或肝性脑病进展
本研究对700例肝硬化门诊患者进行隐匿性肝性脑病(CHE)检测并随访2年,用Cox回归分析显性肝性脑病(OHE)发生时间。结果显示 demographics、肝硬化特征及阿片类药物使用与CHE诊断和OHE进展相关,而其他共病无此关联。
要点
- 非肝脏共病不影响CHE诊断或OHE进展
- 阿片类药物使用与CHE诊断和OHE进展相关
- demographics和肝硬化特征预测OHE复发
核心结论
- demographics、肝硬化特征及阿片类药物使用与CHE诊断和OHE进展相关,其他共病无影响。
研究设计与样本
- 肝硬化门诊患者接受CHE检测并随访2年,共700例,采用Cox回归分析OHE发生时间。
主要发现
- 主要共病为高血压(54%)、糖尿病(35%)和抑郁(29%)。
- 常见药物为质子泵抑制剂(49%)、β受体阻滞剂(32%)和阿片类药物(21%)。
- 约90例(40%)既往OHE患者在检测后93(30,206)天复发,仅由肝脏相关变量预测。
临床怎么用
- 评估肝硬化患者CHE和OHE风险时,应关注肝脏相关变量和阿片类药物使用,而非其他共病。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We aimed to determine the effect of comorbidities on covert hepatic encephalopathy (CHE) diagnosis and overt hepatic encephalopathy (OHE) development. METHODS: Cirrhotic outpatients underwent CHE testing and 2-year follow-up. Cox regression was performed for time to OHE. In total, 700 patients (60 years, 84% men, model for end-stage liver disease 11) and 33% prior OHE underwent testing and follow-up. RESULTS: Major comorbidities were hypertension (54%), diabetes (35%), and depression (29%). Common medications were proton pump inhibitor (49%), beta-blockers (32%), and opioids (21%). Approximately 90 (40%) prior-OHE patients developed recurrence 93 (30,206) days post-testing predicted only by liverrelated variables. DISCUSSION: Demographics, cirrhosis characteristics, and opioid use, but not other comorbid conditions, were associated with CHE diagnosis and OHE progression.
引用
- Acharya C, Nadhem O, Shaw J, et al. Liver-Unrelated Comorbid Conditions Do Not Affect Cognitive Performance or Hepatic Encephalopathy Progression in Cirrhosis. Am J Gastroenterol. 2021. PMID: 34140445. doi:10.14309/ajg.0000000000001346
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。